Treatment-free Remission Attempts Feasible in Patients Treated With Second-line Nilotinib for CML-CP

Share this content:
Treatment-free remission attempts in patients with chronic myeloid leukemia (CML), who have discontinued second-line nilotinib therapy.
Treatment-free remission attempts in patients with chronic myeloid leukemia (CML), who have discontinued second-line nilotinib therapy.

Treatment-free remission attempts in patients with chronic myeloid leukemia (CML), who have discontinued second-line nilotinib therapy after achieving a deep molecular response, are safe and likely to be achievable in the majority of patients in this setting, a study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting has shown.1

For this single-arm, phase 2 trial, researchers enrolled 163 patients with CML in chronic phase who were treated with a tyrosine kinase inhibitor for at least 3 years, including imatinib for more than 4 weeks followed by nilotinib for at least 2 years, and who had achieved a deep molecular response with niolotinib.

Patients continued nilotinib for 1 year, at which point patients without confirmed loss of deep molecular response were eligible to discontinue nilotinib. Upon confirmed loss of deep or major molecular response, nilotinib was reinitiated.

Results showed that 126 patients entered treatment-free remission after a median therapy duration  of 53 months. Of these patients, 57.9% (95% CI, 48.8-66.7) remained in treatment-free remission at 48 weeks.

Researchers found that during treatment-free remission, 18 patients had confirmed loss of deep molecular response, 34 lost major molecular response, and 1 patient came off the study due to atypical transcript. Of the 51 patients who reinitiated nilotinib, 98% re-achieved at least a major molecular response and most regained a deep molecule response.

RELATED: CML: Increased qPCR Testing Frequency Reduces Hospital Visits

No new safety signals were observed on nilotinib treatment. All grade musculoskeletal pain (42.1% versus 14.3%) and fluid retention (10.3% versus 1.6%) occurred more frequently in treatment-free remission group, in contrast with patients receiving nilotinib consolidation.
Cardiovascular events were more common in the nilotinib group (4.8% versus 0%).                                  

Reference

  1. Hughes TP, Boquimpani C, Kim DW, Benyamini N, Clementino NC, Shuvaev V, et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study. J Clin Oncol. 2016; 34 (suppl; abstr 7054).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters